Upstream Bio Announces Addition to Russell 2000® Index

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB) announced its upcoming addition to the Russell 2000® Index, effective December 23, 2024, as part of the fourth quarter IPO additions. The Russell 2000® Index, which measures the performance of the U.S. small-cap equity market segment, is widely used by investment managers and institutional investors for index funds and investment strategy benchmarking. The index represents approximately 10% of the total market capitalization of the Russell 3000® Index, including about 2,000 of the smallest securities. Notably, approximately $10.5 trillion in assets are benchmarked against Russell US indexes as of December 2023.

Positive

• Inclusion in Russell 2000® Index increases visibility to institutional investors
• Potential for increased trading volume and liquidity due to index fund inclusion
• Access to $10.5 trillion benchmark-linked investment pool

Negative

• None.

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.  

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, a prominent global index provider.

The Russell 2000^® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000^® Index is a subset of the Russell 3000^® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. IPOs are added to the Russell US indexes on a quarterly basis. For more information, go to the “Russell US Index IPO additions and reports” section on the FTSE Russell website.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as "aims," "anticipates," "believes," “continue,” "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," “predict,” “project,” "seeks," “should,” “target,” "will" and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding the expected addition of the Company to the Russell 2000® index. Any forward-looking statements in this press release are based on Upstream’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Upstream’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream’s ability to fund its development activities and achieve development goals; Upstream’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream’s competitors and industry; and other risks and uncertainties described in Upstream’s current and future filings with the SEC, including those described from time to time under the caption “Risk Factors.” Upstream explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

FAQ

When will Upstream Bio (UPB) be added to the Russell 2000 Index?

Upstream Bio will be added to the Russell 2000® Index on December 23, 2024, at the open of U.S. equity markets.

What is the significance of UPB joining the Russell 2000 Index?

Joining the Russell 2000® Index increases UPB's visibility to institutional investors and index funds, potentially improving trading volume and liquidity, with access to approximately $10.5 trillion in benchmark-linked assets.

How many companies are included in the Russell 2000 Index with UPB?

The Russell 2000® Index includes approximately 2,000 of the smallest securities based on market cap and current index membership, representing about 10% of the Russell 3000® Index's total market capitalization.

What is the total asset value benchmarked against Russell US indexes that UPB will be part of?

According to December 2023 data, approximately $10.5 trillion in assets are benchmarked against the Russell US indexes.